Trademark: 90144485
Word
ZEAL & ZEALAND PHARMA
Status Date
Tuesday, February 21, 2023
Registration Number
6986947
Registration Date
Tuesday, February 21, 2023
Filing Date
Friday, August 28, 2020
Published for Opposition
Tuesday, October 19, 2021
41 (Based on Use in Commerce) Publication of articles and scientific text and posters featuring the results of clinical trials for pharmaceutical preparations related to diabetes, obesity and gastrointestinal diseases; providing educational seminars, educational exhibitions, conferences and training courses, all in the field of diabetes, obesity and gastrointestinal diseases; educational seminars, educational exhibitions, conferences and instructional services relating to medical treatments in the field of diabetes, obesity and gastrointestinal diseases; educational services, namely, organizing and conducting educational programs, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity and gastrointestinal diseases
5 (Based on 44(e)) Pharmaceutical preparations for the treatment of diabetes, obesity and gastrointestinal diseases; synthetic peptides for pharmaceuticals purposes for the treatment of diabetes, obesity and gastrointestinal diseases; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, namely, pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes containing insulin or glucagon or analogues of those
16 (Based on Use in Commerce) printed pharmaceutical information leaflets in the field of diabetes, obesity and gastrointestinal diseases; printed publications, namely, books, magazines, periodicals and manuals, all in the field of diabetes, obesity and gastrointestinal diseases; printed instructional or teaching matter in the field of diabetes, obesity and gastrointestinal diseases; printed instructional and teaching materials about diagnosing and treatment of diabetes, obesity and gastrointestinal diseases; printed guidelines for diagnosing and treatment of diabetes, obesity and gastrointestinal diseases
35 (Based on 44(e)) Marketing services; customer relationship management; business administrative services for medical referrals; patient relationship management services; business administration of pharmacy and pharmaceutical benefit plans
45 (Based on 44(e)) Licensing of patent and intellectual property rights arising from medical and pharmaceutical research and development activities; licensing of proprietary intellectual property
44 (Based on 44(e)) Medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; clinical trials; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing web-based on-line portals that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely, providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid
10 (Based on Use in Commerce) Medical apparatus and instruments, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; blood glucose monitors for medical purposes; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods; wearable health devices for insulin monitoring
42 (Based on 44(e)) Scientific and technological services, namely, research and design in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; providing websites featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely, providing a website featuring technology that enables users to obtain data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases
The mark consists of the wording "ZEAL&" with each letter appearing in white, in a blue circle, an overlapped grey circle, an overlapped yellow circle, an overlapped turquoise circle, a red circle, from left to right, with the grey wording "ZEALAND PHARMA" written below.
ZEAL AND ZEALAND PHARMACY; ZEAL AND ZEALAND PHARMACEUTICALS
The color(s) grey, yellow, turquoise, red, white and blue is/are claimed as a feature of the mark.
"ZEALAND PHARMA"
Feb 21, 2023
Notice Of Registration Confirmation Emailed
Feb 21, 2023
Registered-Principal Register
Jan 14, 2023
Notice Of Acceptance Of Statement Of Use E-Mailed
Jan 13, 2023
Allowed Principal Register - Sou Accepted
Dec 17, 2022
Assigned To Examiner
Nov 15, 2022
Statement Of Use Processing Complete
Oct 27, 2022
Use Amendment Filed
Nov 15, 2022
Case Assigned To Intent To Use Paralegal
Oct 27, 2022
Teas Statement Of Use Received
Jun 23, 2022
Assignment Of Ownership Not Updated Automatically
Jun 9, 2022
Notice Of Approval Of Extension Request E-Mailed
Jun 7, 2022
Sou Extension 1 Granted
Jun 7, 2022
Sou Extension 1 Filed
Jun 7, 2022
Teas Extension Received
Feb 4, 2022
Assignment Of Ownership Not Updated Automatically
Dec 14, 2021
Noa E-Mailed - Sou Required From Applicant
Oct 19, 2021
Official Gazette Publication Confirmation E-Mailed
Oct 19, 2021
Published For Opposition
Sep 29, 2021
Notification Of Notice Of Publication E-Mailed
Sep 13, 2021
Law Office Publication Review Completed
Sep 12, 2021
Assigned To Lie
Sep 11, 2021
Approved For Pub - Principal Register
Sep 11, 2021
Examiner's Amendment Entered
Sep 11, 2021
Notification Of Examiners Amendment E-Mailed
Sep 11, 2021
Examiners Amendment E-Mailed
Sep 11, 2021
Examiners Amendment -Written
Sep 9, 2021
Previous Allowance Count Withdrawn
Sep 7, 2021
Withdrawn From Pub - Og Review Query
Aug 24, 2021
Approved For Pub - Principal Register
Aug 24, 2021
Examiner's Amendment Entered
Aug 24, 2021
Notification Of Examiners Amendment E-Mailed
Aug 24, 2021
Examiners Amendment E-Mailed
Aug 24, 2021
Examiners Amendment -Written
Aug 5, 2021
Notification Of Final Refusal Emailed
Aug 5, 2021
Final Refusal E-Mailed
Aug 5, 2021
Final Refusal Written
Aug 3, 2021
Teas/Email Correspondence Entered
Aug 3, 2021
Correspondence Received In Law Office
Aug 3, 2021
Teas Response To Office Action Received
Jul 27, 2021
Notification Of Non-Final Action E-Mailed
Jul 27, 2021
Non-Final Action E-Mailed
Jul 27, 2021
Non-Final Action Written
Jun 25, 2021
Teas/Email Correspondence Entered
Jun 25, 2021
Correspondence Received In Law Office
Jun 25, 2021
Teas Response To Office Action Received
Jan 7, 2021
Notification Of Non-Final Action E-Mailed
Jan 7, 2021
Non-Final Action E-Mailed
Jan 7, 2021
Non-Final Action Written
Dec 30, 2020
Assigned To Examiner
Oct 2, 2020
Notice Of Design Search Code E-Mailed
Oct 1, 2020
New Application Office Supplied Data Entered
Sep 1, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
